Trials / Completed
CompletedNCT04361513
Genicular Nerve Block in Rheuamtoid Arthritis
Genicular Nerve Block in Rheumatoid Arthritis: a Prospective Randomized Clinical Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Sohag University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
N=64 RA patients either early or established disease diagnosed after ACR/EULAR criteria 2010 with unilateral persistent knee arthritis. They were randomly assigned into two groups; group 1 received genicular nerve block, group 2 intra-articular triamcinolone. Both groups were examined by SOLAR scoring system, Visual analogue scale (VAS) and Lysholm score at 0, 2 and 12 weeks. A semi-quantitative score was used to assess tenderness and swelling at the same intervals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) | 3 point genicular nerve block |
| DRUG | triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) | intra-articular injection of triamcinilone |
Timeline
- Start date
- 2020-04-15
- Primary completion
- 2020-07-28
- Completion
- 2020-07-28
- First posted
- 2020-04-24
- Last updated
- 2021-06-25
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04361513. Inclusion in this directory is not an endorsement.